1. Home
  2. MODD vs APRE Comparison

MODD vs APRE Comparison

Compare MODD & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

N/A

Current Price

$2.17

Market Cap

11.2M

Sector

Health Care

ML Signal

N/A

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.78

Market Cap

10.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
APRE
Founded
1998
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.8M
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
MODD
APRE
Price
$2.17
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $4.10
AVG Volume (30 Days)
150.6K
★ 220.9K
Earning Date
02-17-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.22
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.55
52 Week High
$6.16
$1.69

Technical Indicators

Market Signals
Indicator
MODD
APRE
Relative Strength Index (RSI) 39.28 47.33
Support Level $0.28 $0.59
Resistance Level $2.49 $0.81
Average True Range (ATR) 0.29 0.06
MACD -0.06 -0.01
Stochastic Oscillator 7.53 23.51

Price Performance

Historical Comparison
MODD
APRE

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: